|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yazici C, Niemeyer DJ, Iannitti DA and
Russo MW: Hepatocellular carcinoma and cholangiocarcinoma: An
update. Expert Rev Gastroenterol Hepatol. 8:63–82. 2014. View Article : Google Scholar
|
|
3
|
Patrikidou A, Sinapi I, Regnault H, Fayard
F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M and Boige
V: Gemcitabine and oxaliplatin chemotherapy for advanced
hepatocellular carcinoma after failure of anti-angiogenic
therapies. Invest New Drugs. 32:1028–1035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qin LF and Ng IO: Induction of apoptosis
by cisplatin and its effect on cell cycle-related proteins and cell
cycle changes in hepatoma cells. Cancer Lett. 175:27–38. 2002.
View Article : Google Scholar
|
|
6
|
Frenzel A, Grespi F, Chmelewskij W and
Villunger A: Bcl2 family proteins in carcinogenesis and the
treatment of cancer. Apoptosis. 14:584–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei W, Chua MS, Grepper S and So SK:
Blockade of Wnt-1 signaling leads to anti-tumor effects in
hepatocellular carcinoma cells. Mol Cancer. 8:762009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venkatesan B, Prabhu SD, Venkatachalam K,
Mummidi S, Valente AJ, Clark RA, Delafontaine P and Chandrasekar B:
WNT1-inducible signaling pathway protein-1 activates diverse cell
survival pathways and blocks doxorubicin-induced cardiomyocyte
death. Cell Signal. 22:809–820. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Germano D and Daniele B: Systemic therapy
of hepatocellular carcinoma: Current status and future
perspectives. World J Gastroenterol. 20:3087–3099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coulouarn C, Corlu A, Glaise D, Guénon I,
Thorgeirsson SS and Clément B: Hepatocytestellate cell cross-talk
in the liver engenders a permissive inflammatory microenvironment
that drives progression in hepatocellular carcinoma. Cancer Res.
72:2533–2542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trimboli AJ, Cantemir-Stone CZ, Li F,
Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H,
Chong JL, et al: Pten in stromal fibroblasts suppresses mammary
epithelial tumours. Nature. 461:1084–1091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nelson CM and Bissell MJ: Of extracellular
matrix, scaffolds, and signaling: Tissue architecture regulates
development, homeostasis, and cancer. Annu Rev Cell Dev Biol.
22:287–309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polyak K, Haviv I and Campbell IG:
Co-evolution of tumor cells and their microenvironment. Trends
Genet. 25:30–38. 2009. View Article : Google Scholar
|
|
16
|
Hao H, Liu M, Wu P, Cai L, Tang K, Yi P,
Li Y, Chen Y and Ye D: Lipoxin A4 and its analog suppress
hepatocellular carcinoma via remodeling tumor microenvironment.
Cancer Lett. 309:85–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alazawi W, Cunningham M, Dearden J and
Foster GR: Systematic review: Outcome of compensated cirrhosis due
to chronic hepatitis C infection. Aliment Pharmacol Ther.
32:344–355. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hernandez-Gea V and Friedman SL:
Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011.
View Article : Google Scholar
|
|
22
|
Amann T, Bataille F, Spruss T, Mühlbauer
M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK and Hellerbrand
C: Activated hepatic stellate cells promote tumorigenicity of
hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang BB, Cheng JY, Gao HH, Zhang Y, Chen
ZN and Bian H: Hepatic stellate cells in
inflammation-fibrosis-carcinoma axis. Anat Rec (Hoboken).
293:1492–1496. 2010. View
Article : Google Scholar
|
|
24
|
Jia YL, Shi L, Zhou JN, Fu CJ, Chen L,
Yuan HF, Wang YF, Yan XL, Xu YC, Zeng Q, et al: Epimorphin promotes
human hepatocellular carcinoma invasion and metastasis through
activation of focal adhesion kinase/extracellular signal-regulated
kinase/matrix metalloproteinase-9 axis. Hepatology. 54:1808–1818.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nieto N and Cederbaum AI: Increased
Sp1-dependent transactivation of the LAMgamma 1 promoter in hepatic
stellate cells co-cultured with HepG2 cells overexpressing
cytochrome P450 2E1. J Biol Chem. 278:15360–15372. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang HY and Sun H: Up-regulation of Foxp3
inhibits cell proliferation, migration and invasion in epithelial
ovarian cancer. Cancer Lett. 287:91–97. 2010. View Article : Google Scholar
|
|
27
|
Guo LY, Li YM, Qiao L, Liu T, Du YY, Zhang
JQ, He WT, Zhao YX and He DQ: Notch2 regulates matrix
metallopeptidase 9 via PI3K/AKT signaling in human gastric
carcinoma cell MKN-45. World J Gastroenterol. 18:7262–7270. 2012.
View Article : Google Scholar
|
|
28
|
Mohla S and Witz IP: The 5th International
Conference on Tumor Microenvironment: Progression, therapy and
prevention. Versailles, France, October 20–24, 2009: conference
summary. Cancer Microenviron. 3:1–5. 2010. View Article : Google Scholar
|
|
29
|
Mbeunkui F and Johann DJ Jr: Cancer and
the tumor microenvironment: A review of an essential relationship.
Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar
|
|
30
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
31
|
Qayed M and Katzenstein HM: Dose-intensive
cisplatin for hepatoblastoma: Have you heard? Lancet Oncol.
14:791–792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Tan G, Dong L, Cheng L, Li K, Wang
Z and Luo H: Circulating MiR-125b as a marker predicting
chemoresistance in breast cancer. PLoS One. 7:e342102012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gatz SA and Wiesmüller L: p53 in
recombination and repair. Cell Death Differ. 13:1003–1016. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pandit B and Gartel AL: Proteasome
inhibitors induce p53-independent apoptosis in human cancer cells.
Am J Pathol. 178:355–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
